| 1989 |
Complete amino acid sequence of human histone H1d (H1-3) was determined, establishing it as a 212-residue protein with an acetylated N-terminal serine, showing sequence conservation in the ~70 internal (globular domain) residues but variation in N-terminal and C-terminal regions compared to other H1 variants. |
Protein sequencing (chymotryptic digestion, carboxypeptidase digestion, N-terminal sequencing) |
Journal of biochemistry |
High |
2613692
|
| 1990 |
A rat genomic clone encoding histone H1d (H1-3 ortholog) was isolated; in vitro transcription and translation of the gene produced a protein whose electrophoretic mobility matched the H1d variant, confirming gene identity. |
Genomic cloning, SP6 RNA polymerase transcription, cell-free translation, SDS-PAGE mobility comparison |
Gene |
Medium |
2373370
|
| 1998 |
Recombinant rat histone H1d (H1-3 ortholog) expressed in E. coli was shown to (a) condense DNA and (b) bind specifically to synthetic four-way junction DNA, establishing these biochemical activities for the purified protein. |
Recombinant protein expression (pTrc99A, 6-His tag), Ni2+-NTA and heparin-agarose purification, DNA condensation assay, four-way junction DNA binding assay |
Protein expression and purification |
Medium |
9473455
|
| 2003 |
The rat H1d (H1-3 ortholog) gene contains an intragenic activating region (IAR) at +21 to +116 that confers 2–3-fold upregulation of expression; two Omega elements at +32 and +66 account for the activating effect, and a YY1/alpha-like site overlaps the translational start codon. These elements bind proteins similar to those binding the mouse H3.2 CRAS. |
Transient transfection reporter assays (NIH3T3 cells), targeted mutagenesis, stepwise deletions, gel-shift (EMSA) assays with transcription factor YY1 |
Biochimica et biophysica acta |
Medium |
12531475
|
| 2009 |
H1.3 (H1-3) and its C-terminal fragment N.1 (generated by Asp-N endoproteinase cleavage at the single aspartate) selectively inhibit gamma-thrombin-induced platelet aggregation via the PAR-4 receptor; removal of two N-terminal amino acids (Asp-Val) from N.1 further enhanced PAR-4 inhibitory activity. |
Platelet aggregation assay, proteolytic fragmentation of H1.3, MALDI mass spectrometry for fragment identification |
Platelets |
Medium |
19637099
|
| 2014 |
H1.3 (H1-3) acts as a specific transcriptional repressor of the noncoding oncogene H19 in ovarian cancer cells: overexpression of H1.3 increases its occupancy at the H19 imprinting control region (ICR), concomitant with increased DNA methylation and reduced CTCF occupancy at the ICR, suppressing H19 expression and decreasing cell growth. |
H1.3 overexpression and knockdown in OVCAR-3 cells, ChIP (chromatin immunoprecipitation) for H1.3 occupancy at H19 ICR, bisulfite sequencing for DNA methylation, colony formation and growth rate assays |
Cancer research |
High |
25205099
|
| 2015 |
H1.3 (H1-3) forms a novel complex with HDAC3, SMRT, and NCoR that accumulates in late G2 and mitosis in HeLa cells; HDAC3 deacetylase activity in this complex is activated only during mitosis upon phosphorylation of HDAC3 at Ser-424 by protein kinase CK2. H1.3 and HDAC3 co-localize between chromosomes, with polar microtubules and spindle poles during metaphase through telophase, suggesting H1.3 targets HDAC3 to microtubules. |
Co-immunoprecipitation from synchronized HeLa cells, in vitro kinase assay (CK2 phosphorylation of HDAC3 in isolated complexes), HDAC activity assay, CK2α/CK2α' double knockdown, immunofluorescence co-localization |
The Journal of biological chemistry |
High |
26663086
|
| 2017 |
HUWE1 E3 ubiquitin ligase binds and ubiquitinates H1.3 (H1-3), targeting it for proteasomal degradation; loss of HUWE1 increases H1.3 protein levels, which in turn represses H19 noncoding RNA expression, inhibiting ovarian cancer cell transformation and tumor growth. |
Co-immunoprecipitation (HUWE1–H1.3 interaction), ubiquitination assay, Huwe1 genetic deletion in mouse, inducible HUWE1 silencing in human ovarian cancer cells, H1.3 and H19 knockdown rescue experiments |
Cancer research |
High |
28687618
|
| 2022 |
HDAC1 depletion specifically potentiates phosphorylation of H1.2/H1.3 (H1-3) and H1.4 at serine 38, without changing H1 acetylation levels, as revealed by mass spectrometry analysis of post-translational modifications. |
HDAC1 knockdown, mass spectrometry-based PTM analysis of linker histones |
Life (Basel, Switzerland) |
Medium |
35743829
|
| 2024 |
H1.3 (H1-3) is universally enriched at the nuclear periphery and co-localizes with compacted DNA across all human cell lines examined; depletion of H1.3 causes H1.4 and H1.0 to shift toward a more peripheral distribution, indicating H1.3 influences the nuclear distribution of other H1 variants and contributes to chromatin compaction at the lamina. |
Immunofluorescence imaging including super-resolution microscopy, H1 variant knockdown, quantitative distribution analysis across multiple human cell lines |
eLife |
Medium |
38530350
|
| 2025 |
H1.3 (H1-3) interacts with MAVS and IRF3 (confirmed by endogenous and exogenous Co-IP), promotes IRF3 phosphorylation and nuclear translocation, upregulates MDA5 expression, and enhances TBK1 and IRF3 phosphorylation during EMCV infection to boost IFN-β production. The N-terminal domain of H1.3 is identified as critical for regulating the IFN-β signaling pathway. Additionally, EMCV infection increases phosphorylation of H1.3 itself. |
H1.3 overexpression and knockdown in A549 cells, endogenous and exogenous Co-immunoprecipitation (H1.3–MAVS and H1.3–IRF3), immunoblotting for TBK1/IRF3 phosphorylation, nuclear fractionation for IRF3 translocation, N-terminal domain deletion analysis, viral replication assay |
Molecular immunology |
Medium |
40580683
|
| 2026 |
In AML cells, H1.3 (H1-3) is enriched in high-GC-content chromatin regions and co-localizes with repressive H3K27me3 mark, consistent with a role in chromatin compaction and transcriptional repression. Knockout of H1.3 causes H1.2 to redistribute from its normal chromatin regions to H1.3-occupied regions, leading to chromatin alterations and changes in interferon-related signaling and cell cycle gene programs. |
ChIP-seq chromatin mapping, transcriptomic analysis (RNA-seq), H1.3 CRISPR knockout in AML cells, H1.2 ChIP-seq redistribution analysis |
Epigenetics & chromatin |
High |
42098859
|